Ovarian Stimulation in IVF is a critical process designed to maximize the number of mature eggs retrieved for in vitro fertilization. This comprehensive guide, perfect for students, will break down the physiology, protocols, monitoring, and key performance indicators of ovarian stimulation. Understanding these elements is essential for grasping how IVF aims to overcome natural cycle limitations and improve success rates.
Understanding Ovarian Stimulation in IVF: The Basics
In a natural menstrual cycle, typically only one dominant follicle matures, while others undergo Atresia (programmed cell death). Ovarian stimulation overrides this natural process by keeping the FSH (Follicle-Stimulating Hormone) window open longer, allowing more follicles to grow simultaneously.
Three fundamental concepts underpin ovarian stimulation:
- The Window: This refers to how long FSH levels remain above the threshold required for follicle growth. In stimulated cycles, this window is extended.
- The Threshold: Each follicle has a unique sensitivity to FSH. Lower-threshold follicles are recruited first, while stimulation aims to recruit higher-threshold follicles too.
- Atresia: This is the default fate for most follicles. Ovarian stimulation is essentially a rescue mission, preventing follicles from undergoing atresia and allowing them to mature.
This deliberate intervention aims to yield more oocytes, leading to more usable embryos and a higher cumulative live birth rate, while managing tradeoffs like Ovarian Hyperstimulation Syndrome (OHSS), cost, and patient burden.
Building Blocks of Ovarian Stimulation Protocols
Successful ovarian stimulation relies on a combination of specific medications and strategies. These building blocks ensure follicles grow appropriately and the cycle is controlled.
FSH Products: The Engine of Stimulation
FSH products are the primary driver of follicular growth. They come in several forms:
- Recombinant FSH (rFSH): Examples include Follitropin alfa (Gonal-F, Bemfola, Ovaleap), Follitropin beta (Puregon), Follitropin delta (Rekovelle), and Corifollitropin alfa (Elonva, a long-acting option). Biosimilars like Bemfola and Ovaleap are now established, offering clinically equivalent and cost-effective alternatives.
- Urinary FSH: Highly purified urinary FSH (Fostimon) and Human Menopausal Gonadotropin (hMG, e.g., Menopur), which contains both FSH and LH activity. For embryologists, the dose and timing are more critical than the specific product chosen.
LH Activity: When It Matters
LH (Luteinizing Hormone) plays three key roles:
- Theca androgen substrate: LH stimulates theca cells to produce androgens, which granulosa cells convert to estradiol.
- Granulosa LH receptors: FSH induces LH receptors, allowing larger follicles to respond directly to LH.
- The surge: The natural LH surge triggers crucial final maturation steps.
While most patients have sufficient endogenous LH, exogenous LH activity (e.g., from hMG or rLH like Luveris) is clearly indicated for patients with hypogonadotropic hypogonadism. Its benefit in other groups, such as older women or deeply suppressed antagonist patients, is contested with weaker evidence.
Surge Suppression: Preventing Premature Ovulation
Preventing a premature LH surge is crucial to avoid losing the cycle. Common strategies include:
- Long Agonist Protocol: This original method uses a GnRH agonist to initially cause a